Essential Pharma names Becki Morison as CEO from July 2026
Essential Pharma has appointed Becki Morison as Chief Executive Officer, effective 1 July 2026. Morison joins from LEO Pharma, where she served as Executive Vice President with responsibility for global commercial functions including marketing, medical affairs, and pricing and market access. She succeeds Simon Ball, who has held the interim CEO position since November 2025 and will now serve as President of the company's Rare Disease business unit.
Morison brings more than 25 years of pharmaceutical leadership to the role. Before joining LEO Pharma, she spent over two decades at Eli Lilly in roles of increasing seniority, leading its Neuroscience franchise, its Australia/New Zealand affiliate, and its Northern European Hub, which covered six countries through a period of major strategic transition.
Track record in rare and niche pharma
Her most notable recent role was overseeing LEO Pharma's dermatology portfolio, including the global launch of tralokinumab, an anti-interleukin-13 monoclonal antibody approved for moderate-to-severe atopic dermatitis. That experience in specialty biologics and niche-population medicine aligns closely with Essential Pharma's strategic priorities.
Essential Pharma's portfolio currently reaches patients in around 70 countries across rare disease, CNS, ophthalmology, and gastroenterology. The company also disclosed that its first development-stage asset is an anti-GD2 antibody for high-risk neuroblastoma, an aggressive childhood cancer with limited treatment options.
Lee Morley, Chairman of Essential Pharma, said Morison's "rare combination of global commercial leadership, rare disease experience, and proven ability to transform organisations" made her the right choice for the company's next stage. Morison said the opportunity to lead a company "focused entirely on delivering medicines for underserved and rare disease patient populations" was one she found "deeply motivating."
Market context and leadership structure
The appointment also clarifies the company's internal structure. With Simon Ball moving to lead the Rare Disease unit and Lewis Pearson in place as President of Established Brands, Essential Pharma now runs two dedicated business lines under a single group CEO, a structure increasingly common among mid-tier specialty pharma companies seeking to balance legacy revenue from established brands with higher-risk development activity.
The rare disease sector remains a strategic priority for specialty pharma operators across Europe. Orphan designation incentives from the EMA and the FDA continue to attract investment, and the commercial bar for market access in small-population indications has shifted substantially as payers in the UK, Germany, and France apply more rigorous health technology assessments to high-cost orphan therapies. Morison's background in pricing and market access is therefore particularly relevant given the reimbursement complexity Essential Pharma will face as it advances the neuroblastoma programme toward later-stage development.
Near-term milestones for the company are likely to centre on the anti-GD2 antibody programme and the continued commercialisation of its established brands across its international network. Investors and partners will be watching for updates on the development timeline and any partnership or licensing activity as Morison formally takes the helm next month.